These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31841026)

  • 1. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial.
    Israelsen M; Dahl EK; Madsen BS; Wiese S; Bendtsen F; Møller S; Fialla AD; Jensen BL; Krag A
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G313-G321. PubMed ID: 31841026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
    Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
    Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.
    Bai Z; An Y; Guo X; Teschke R; Méndez-Sánchez N; Li H; Qi X
    Can J Gastroenterol Hepatol; 2020; 2020():5106958. PubMed ID: 32676484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis.
    Kalambokis GN; Tsiakas I; Christaki M; Koustousi C; Christou L; Baltayiannis G; Christodoulou D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):659-667. PubMed ID: 29432366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
    Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
    Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
    Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study.
    Therapondos G; Stanley AJ; Hayes PC
    J Gastroenterol Hepatol; 2004 Jan; 19(1):73-7. PubMed ID: 14675246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Developments in Hepatorenal Syndrome.
    Mindikoglu AL; Pappas SC
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):162-177.e1. PubMed ID: 28602971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
    J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.
    Belcher JM; Parada XV; Simonetto DA; Juncos LA; Karakala N; Wadei HM; Sharma P; Regner KR; Nadim MK; Garcia-Tsao G; Velez JCQ; Parikh SM; Chung RT; Allegretti AS;
    Am J Kidney Dis; 2022 May; 79(5):737-745. PubMed ID: 34606933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis.
    Kalambokis G; Economou M; Paraskevi K; Konstantinos P; Pappas C; Katsaraki A; Tsianos EV
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1075-81. PubMed ID: 15955217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
    Zhang J; Rössle M; Zhou X; Deng J; Liu L; Qi X
    Curr Med Res Opin; 2019 May; 35(5):859-868. PubMed ID: 30474439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
    Wong F; Boyer TD; Sanyal AJ; Pappas SC; Escalante S; Jamil K
    Nephrol Dial Transplant; 2020 Sep; 35(9):1554-1561. PubMed ID: 30887050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.
    Hadengue A; Gadano A; Moreau R; Giostra E; Durand F; Valla D; Erlinger S; Lebrec D
    J Hepatol; 1998 Oct; 29(4):565-70. PubMed ID: 9824265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P; Kumar A; Shrama BC; Sarin SK
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.